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OBJECTIVES: High incidence and case fatality of unstable angina (UA) is, to a large extent, a consequence of the
lack of highly sensitive and specific non-invasive markers. Circulating microRNAs (miRNAs) have been widely
recommended as potential biomarkers for numerous diseases. In the present study, we characterized distinctive
miRNA expression profiles in patients with stable angina (SA), UA, and normal coronary arteries (NCA), and
identified promising candidates for UA diagnosis.
METHODS: Serum was collected from patients with SA, UA, and NCA who visited the Department of Cardio-
vascular Diseases of the Meizhou People’s Hospital. Small RNA sequencing was carried out on an Illumina HiSeq
2500 platform. miRNA expression in different groups of patients was profiled and then confirmed based on that
in an independent set of patients. Functions of differentially expressed miRNAs were predicted using gene
ontology classification and Kyoto Encyclopedia of Genes and Genomes pathway analysis.
RESULTS: Our results indicated that circulating miRNA expression profiles differed between SA, UA, and NCA
patients. A total of 36 and 161 miRNAs were dysregulated in SA and UA patients, respectively. miRNA expression
was validated by reverse transcription quantitative polymerase chain reaction.
CONCLUSION: The results suggest that circulating miRNAs are potential biomarkers of UA.
KEYWORDS: Coronary Artery Disease; MicroRNA (miRNA); Stable Angina; Unstable Angina; RNA sequencing
(RNA-seq).
’ INTRODUCTION
Coronary artery disease (CAD) is a major global health
problem (1), and the acute coronary syndrome (ACS), which
is the most severe form of CAD, is the leading cause of death
and disability worldwide (2,3). Early and accurate diagnosis
of ACS is critical for effective treatment, for reducing cardio-
vascular events, and for improving disease prognosis.
CAD is a chronic inflammation which comprises several
stages from chest pain to stable angina (SA) which may
aggravate to more severe unstable angina (UA) or acute
myocardial infarction (AMI) (4). AMI is diagnosed by angio-
graphy and plasma biomarkers such as cardiac troponin (5).
However, relatively few specific biomarkers are available to
distinguish UA from SA, which is critical, as UA is more
likely to produce poor outcomes. Therefore, novel clinical
biomarkers for early diagnosis of UA are required.
MicroRNAs (miRNAs) are endogenous RNAs with a length
of approximately 22–24 nucleotides which post-transcription-
ally control gene expression by targeting the 30-untranslated
region of mRNA (6). It is estimated that miRNAs regulate
about 60% of protein-coding genes that are involved in
various biological processes such as cell growth, differentia-
tion, and apoptosis (7). Many recent studies suggest that
miRNAs play crucial roles in pathophysiologic processes of
cardiovascular diseases (8-10). Moreover, miRNA expression
is associated with atherosclerotic plaque stability (11). miRNAs
are tissue-specific and are traceable in the circulatory sys-
tem, which makes them suitable as diagnostic biomarkers
(12-14). Several studies suggested that certain miRNAs, i.e.,
miR-1, miR133a, miR-133b, and miR-499, are dysregulated
in patients with cardiac injury and myocardial infarction
(15-17). A different study showed that circulating miRNAs
are promising diagnostic and prognostic UA biomarkers
(18). However, only few biomarkers can be used to reliably
distinguish UA from SA; therefore, research on miRNA
candidates is needed to identify useful biomarkers for
UA diagnosis.DOI: 10.6061/clinics/2020/e1546
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In the present study, we examined distinct miRNA profiles
in plasma of SA and UA patients using high-throughput
sequencing. The objective of this study was to identify speci-
fic miRNAs that can be used as biomarkers of UA.
’ MATERIALS AND METHODS
Study subjects
Subjects were recruited from all patients who attended
the Department of Cardiovascular Diseases of the Meizhou
People’s Hospital between January 1, 2017, and December
31, 2018. The study cohort included three groups, i.e., UA
patients, SA patients, and patients with normal coronary
arteries (NCA). Patients were diagnosed angiographically
with CAD if at least one major epicardial vessel showed
450% stenosis. CAD patients were categorized as UA
patients according to the 2014 AHA/ACC guidelines for
management of ACS patients (19), or as SA patients accor-
ding to the ACC/AHA guidelines (20). Patients with no
observable stenosis in the coronary artery, as determined
by coronary angiography, were considered NCA patients.
Clinical history and medication records of patients were
compiled, and subjects were excluded if they had a left ven-
tricular ejection fraction of less than 45% or if they suffered
from congestive heart failure, severe infectious diseases, or
other malignant diseases.
Ethics approval
The study was approved by the Ethical Committee of the
Meizhou People’s Hospital. Written informed consent was
obtained from each subject.
Sample collection
Peripheral venous blood samples were collected after
coronary angiography surgery. Blood samples were placed in
EDTA-coated tubes. Plasma was separated by centrifugation
at 1600 g and 4oC for 10 min. Supernatants were transferred
to new tubes which were then centrifuged at 14,000 g and
4oC for 15 min to produce cell- and platelet-free plasma
samples which were then stored at -80oC until further use.
RNA extraction
RNAwas isolated from plasma using a QIAamp Circulat-
ing Nucleic Acid kit (Qiagen, Valencia, CA, USA) following
the manufacturer’s instructions. The concentration and purity
of the miRNAs were assessed using a NanoDrop-1000 spec-
trophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
For normalization, Caenorhabditis elegans miR-39 (cel-miR-39)
was added to plasma samples after addition of TRIzol, accor-
ding to previously published study (21).
Small RNA sequencing
A total of 3 mg of qualified RNA was used for miRNA
library preparation using a TruSeq Small RNA Library
Preparation Kit (Illumina, San Diego, CA, USA). Briefly,
30- and 50-adaptors were ligated to miRNAs, followed by
reverse transcription (RT) using RT primers. Complementary
DNA (cDNA) was amplified, and the products were sepa-
rated using polyacrylamide gel electrophoresis. Fragments
containing 140–160 bp were recovered to produce cDNA
libraries. Library concentration was measured using a Qubit
2.0 fluorometer (Thermo Fisher Scientific). cDNA libraries
were sequenced on a HiSeq 2500 platform (Illumina). Raw
reads were decoded and annotated as small RNAs and
sequence data were bioinformatically analyzed according to
established methods (22).
RNA sequence data analysis
Raw reads in fastq format were processed to remove low-
quality reads, ambiguous nucleotides, adapter sequences,
and poly-A tails to retain clean reads only. Pre-processed
miRNA datasets were mapped to miRNA reference seq-
uences using miRBase R19 software. Expression values of
specific miRNAs were calculated as transcripts per million
reads (TPM), according to the following equation:
TPM ¼ ðread count 1; 000; 000Þ/total read count:
Target gene analysis
Putative targets of dysregulated miRNAs were predicted
using the three databases miRanda, MicroCosm, and Targets-
can. To improve prediction accuracy, we chose putative targets
that were identified in all three databases. To further explore
potential biological functions of miRNA targets, gene ontol-
ogy (GO) terms classifications and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway analyses were per-
formed. GO classification (regarding biological processes,
cellular components, and molecular functions) was carried
out using the software Database for Annotation Visualization
and Integrated Discovery (42). Pathway analyses were perfor-
med using the KEGG database. In brief, enriched biological
processes, cellular components, molecular functions, and
signaling pathways were selected through hyper-geometric
tests and Fisher’s tests after mapping the potential target
genes to the dataset of GO terms and KEGG pathways. A false
discovery rate o0.05 was considered statistically significant.
Validation of miRNA expression
miRNA expression was detected using a Bulge-Loop
miRNA qRT-PCR Starter Kit (RiboBio Co., Ltd, Guangzhou,
China), according to the manufacturer’s instructions. Briefly,
1 mg miRNAwas used for RT in a polymerase chain reaction
(PCR) thermocycler at 42oC for 42 min and 70oC for 10 min.
A quantitative real-time PCR (qPCR) reaction mix (20 ul)
containing 2 ul RT product, 10 ul SYBR Green mix, 0.8 ul
primers and 6.4 ul distilled water (RiboBio Co., Ltd, Guang-
zhou, China) was prepared, and amplification was carried out
on a Roche LightCycler 480 instrument (Roche, Mannheim,
Germany). cel-miR-39 was used as a spike-in reference, as is
common practice (23,24). The delta cycle threshold (DCt) of
miRNAs of interest was calculated using the following
equation: DCt = Ct[miRNA of interest] - Ct[cel-miR-39].
miRNA expression was calculated using the 2-DDCt method
with an arbitrary value of 1 for the control group.
Statistical analyses
Data were analyzed using GraphPad Prism 5 software
(GraphPad Software Inc., La Jolla, CA, USA). Student’s t-test
was applied to test differences between two groups. A one-
way ANOVA followed by Tukey’s post-hoc test was used to
test differences between more than two groups; p-values
o0.05 were considered statistically significant.
’ RESULTS
Clinical characteristics
Nineteen patient samples were subjected to small RNA
sequencing. Basic clinical characteristics of these patients are
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shown in Table 1. No significant differences in these charac-
teristics were observed between the study groups.
Dysregulated miRNA expression profiles in UA and
SA patients
A total of 1,314 miRNAs were identified, including 987
annotated and 327 novel miRNAs. A hierarchical cluster
analysis indicated distinct miRNA expression profiles in UA,
SA, and NCA patients (Figure 1A). To identify differentially
expressed miRNAs, we used selection criteria of a fold
change42 and a p-valueo0.05. A total of 161 miRNAs were
dysregulated in UA compared to NCA, 105 of which were
upregulated and 56 were downregulated; 36 miRNAs were
differentially expressed in SA compared to NCA, 27 of which
were upregulated and 9 were downregulated (Figure 1B). In
total, 150 miRNAs were unique to the UA group, and 25
miRNAs were unique to the SA group. UA and SA groups
shared 11 differentially expressed miRNAs (Figure 1C).
GO functional analysis and KEGG pathway analysis
GO functional analysis was performed to reveal the
biological functions of target genes of dysregulated miRNAs
between UA, SA, and NCA patients. Target genes of dys-
regulated miRNAs in SA patients were involved in biological
Figure 1 - Differentially expressed miRNAs in patients with SA, UA, and NCA. (A) Cluster analysis of differentially expressed miRNAs in
patients with SA, UA, and NCA. (B) Upregulated and downregulated miRNAs in patients with SA and UA. (C) Venn diagram of
differentially expressed miRNAs in SA and UA patients compared with those of NCA patients. SA, stable angina (SA); UA, unstable
angina; NCA, normal coronary artery.
Table 1 - Clinical characteristics of patients. Means±standard deviations are shown in each case.
Variables NCA (n=5) SA (n=6) UA (n=8) p-value#
Age (years) 57±8.71 63±9.88 61±7.97 0.53
Sex M/F 2 (40%) 4 (66.7%) 5 (62.5%) 0.63
SBP (mmHg) 133±9.51 134.7±12.71 132.9±11.42 0.95
DBP (mmHg) 84.6±2.07 81.8±13.24 78.4±5.7 0.45
Lipid profile
TG (mmol/L) 0.99±0.43 1.1±0.60 2.5±0.81 o0.01
TC (mmol/L) 4.43±0.91 4.41±0.74 4.43±0.63 1.00
HDL-C (mmol/L) 1.40±0.41 1.27±0.16 1.02±0.22 0.06
LDL-C (mmol/L) 2.26±0.51 2.55±0.73 2.48±0.53 0.71
Risk factors
Active smoker (n, %) 1 (20%) 1 (16.7%) 4 (50%) 0.34
Drink (n, %) 1 (20%) 1 (16.7%) 1 (12.5%) 0.93
Hypertension (n, %) 1 (20%) 1 (16.7%) 2 (25%) 0.93
Dyslipidemia (n, %) 1 (20%) 0 (0%) 5 (62.5%) 0.04
Diabetes mellitus (n, %) 1 (20%) 0 (0%) 2 (25%) 0.43
Drug administration
Aspirin (n, %) 2 (40%) 5 (83%) 4 (50%) 0.29
Clopidogrel (n, %) 1 (20%) 3 (50%) 5 (62.5%) 0.32
Statin (n, %) 2 (40%) 6 (100%) 7 (87.5%) 0.04
CCB (n, %) 2 (40%) 4 (67.7%) 6 (75%) 0.63
ACEI (n, %) 0 (0%) 2 (33.3%) 0 (0%) 0.09
#Comparisons between groups were performed using a one-way ANOVA for continuous variables and with a Chi-square test for categorical variables.
SA, stable angina; UA, unstable angina; NCA, normal coronary arteries; M/F, male/female; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG,
triglyceride; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; CCB, calcium channel blocker;
ACEI, angiotensin-converting enzyme inhibitor.
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processes such as cellular metabolism, cellular macrom-
olecule metabolism, multicellular organismal development,
and other biological processes (Figure 2A), whereas in UA
patients, targets of dysregulated miRNAs were associated
with biological processes such as protein phosphorylation,
transcription, DNA-dependent, cell adhesion (Figure 2B).
Furthermore, KEGG analysis revealed that dysregulated
miRNAs in the SA group were associated with pathways
such as MAPK signaling, B cell receptor signaling, and apop-
tosis (Figure 3A), whereas differentially expressed miRNAs
in UA group were associated with the Wnt, PI3KAkt, and
MAPK pathways (Figure 3B).
Validation of differentially expressed miRNAs
To assess expression of miRNAs, we randomly selected
eight miRNAs and examined their expression by RT-qPCR
(Table 2). Expression of these miRNAs was assessed in
independent sets of patients with UA (n=15), SA (n=15), and
NCA (n=15), and the expression pattern was different in
UA and SA patients as compared to that in NCA patients
Figure 2 - GO terms analysis of differentially expressed miRNAs in SA and UA patients compared with NCA patients. (A) Enriched GO
terms of differentially expressed miRNAs in SA patients compared with NCA patients. (B) Enriched GO terms of differentially expressed
miRNAs in UA patients compared with NCA patients. The top-20 GO terms of biological processes, cellular components, and molecular
functions are shown. Each GO term has a corrected p-value o0.05. GO, gene ontology; SA, stable angina (SA); UA, unstable angina;
NCA, normal coronary artery.
Figure 3 - KEGG pathway analysis of differentially expressed miRNAs in SA and UA patients compared with NCA patients. (A) Enriched
top-20 pathways of differentially expressed miRNAs in SA patients compared with NCA patients. (B) Enriched top-20 pathways of
differentially expressed miRNAs in UA patients compared with NCA patients. Rich factor: the ratio of candidate genes enriched in the
pathway to total genes in the pathway. KEGG, Kyoto Encyclopedia of Genes and Genomes; SA, stable angina (SA); UA, unstable angina;
NCA, normal coronary artery.
4
Circulating RNA expression in SA and UA
Liu S et al.
CLINICS 2020;75:e1546
(Figure 4), which was consistent with the RNA sequencing
results.
’ DISCUSSION
We examined expression profiles of circulating miRNA in
patients with UA, SA, and NCA. Our results revealed that
SA and UA patients had different miRNA profiles compared
with NCA patients; most dysregulated miRNAs occurred at
higher levels in SA and UA patients than in NCA patients,
and UA patients showed more dysregulated miRNAs than
SA patients.
ACS is still one of the most severe threats to global pub-
lic health (25,26). UA is a major form of ACS, however, only
few specific biomarkers are available for diagnosis. There-
fore, non-invasive sensitive biomarkers of UA are urgently
required. miRNAs occur in body fluids and remain stable
even under severe conditions (27-29). These characteristics
make them ideal candidates as noninvasive biomarkers for
many diseases. Recent studies suggest that miRNAs are
potential diagnostic biomarkers of cardiovascular diseases
such as heart failure (30) and AMI (16). A different study
showed that miR-499-5p can be used to distinguish con-
gestive heart failure from non-ST-segment elevation myo-
cardial infarction patients (31). Moreover, miR-135a, miR-
378, and miR-147 are effective biomarkers of CAD (32), and
miR-208b, miR-499, and miR-1 are associated with the
development of ACS and can thus be used as biomarkers
of AMI (33). In the present study, we found 36 miRNAs that
were dysregulated in SA patients and 161 in UA patients.
These miRNAs may be attributed to the progression of CAD.
Moreover, 11 miRNAs were dysregulated in both SA and UA
patients. These consistently dysregulated miRNAs may be
strongly associated with the development of CAD and thus
appear to be particularly promising candidates for early
detection of ACS.
miRNAs regulate gene expression. We, therefore, pre-
dicted the functions of differentially expressed miRNAs
using GO terms classification and KEGG pathway analysis.
We found that differentially expressed miRNAs regulated
inflammation-associated processes such as cell adhesion and
the MAPK signaling pathway (34,35). Furthermore, the Wnt
pathway, which was also targeted in our study, is involved
in endothelial injury, macrophage activation, and vascular
smooth muscle migration, and these processes are closely
associated with onset and progression of atherosclerosis (36).
Previous studies showed that miR-1 is associated with
cardiac injury and cardioprotection, and is increased in
patients suffering from AMI (37). miR-142 is increased in
atherosclerotic plaques and regulates oxLDL-induced apop-
tosis in macrophages; moreover, it can be used to predict
major adverse cardiovascular events in CAD patients (38). In
line with these observations, we observed increased levels of
miR-1-3p and miR-142-3p in SA and UA patients, compared
to those in NCA patients, which suggested their correlation
with CAD progression.
Table 2 - Dysregulated miRNAs in patients with UA and SA compared to those of NCA patients.
miRNAs
UA vs. NCA SA vs. NCA
log2FC p Regulation log2FC p Regulation
miR-7109-3p 6.28 0.0005 up 4.96 0.0020 up
miR-6515-3p 4.00 0.0025 up 4.10 0.0069 up
miR-1273g-3p 3.36 0.0013 up 3.45 0.0020 up
miR-20b-5p 3.30 7.33E-06 up 2.55 0.013 up
miR-6793-5p 2.86 0.0032 up 2.77 0.0173 up
miR-142-3p 2.45 5.19E-06 up 2.46 0.0109 up
miR-1-3p 2.44 0.0002 up 2.44 0.01 up
miR-30b-5p 1.84 0.0365 up 2.20 0.0297 up
SA, stable angina; UA, unstable angina; NCA, normal coronary artery; FC, fold change.
Figure 4 - Validation of differentially expressed miRNAs by RT-qPCR. Expression patterns of eight differentially expressed miRNAs were
examined in independent sets of SA (n=15), UA (n=15), and NCA (n=15) patients by RT-qPCR; statistical significance is indicated as
follows: *po0.05; **po0.01; ***po0.001.
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Currently, there is no consensus regarding internal refer-
ences for circulating miRNAs. U6 was used as a reference in
some studies, but it easily degrades in serum (39). However,
miR-16 and miR-1228 are consistently expressed in serum
(40,41). In the present study, we observed that miR-16
expression varied between patients, and miR-1228 was
decreased in UA patients. Recently, non-human spike-in
miRNAs such as cel-miR-39 and cel-miR-67 have been
commonly used as alternative references for normalization
(21,23). Therefore, we used cel-miR-39 to normalize miRNA
levels between different subjects.
There are some limitations of the present study which
should be noted. Firstly, we profiled miRNA expression in
SA and UA patients, however, we were unable to identify
miRNAs that can be used to distinguish UA from SA.
Secondly, white blood cells have not been examined in the
present study, which may bias the generated profiles of
circulating miRNAs.
In conclusion, we identified distinct circulating miRNA
expression profiles in patients with UA and SA by small
RNA sequencing. Dysregulated miRNAs were functionally
associated with pathogenesis of CAD and are thus promising
non-invasive biomarkers for early diagnosis of UA.
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